COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler; Elisabeth G E de Vries; Corine H GeurtsvanKessel; John B Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal

doi:10.1038/s41571-022-00610-8

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler, Elisabeth G E de Vries, Corine H GeurtsvanKessel, John B Haanen, Bernhard Wörmann, Samra Turajlic, Marie von Lilienfeld-Toal

Research output: Contribution to journal › Review article › peer-review

160 Citations (Scopus)

141 Downloads (Pure)

Abstract

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

Original language	English
Pages (from-to)	385–401
Number of pages	17
Journal	Nature Reviews Clinical Oncology
Volume	19
Early online date	11-Mar-2022
DOIs	https://doi.org/10.1038/s41571-022-00610-8
Publication status	Published - Jun-2022

Access to Document

10.1038/s41571-022-00610-8

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safetyFinal publisher's version, 2.86 MBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{62492b799eec48f18256bc0124001930,

title = "COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety",

abstract = "Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.",

author = "Annika Fendler and \{de Vries\}, \{Elisabeth G E\} and GeurtsvanKessel, \{Corine H\} and Haanen, \{John B\} and Bernhard W{\"o}rmann and Samra Turajlic and \{von Lilienfeld-Toal\}, Marie",

note = "{\textcopyright} 2022. Springer Nature Limited.",

year = "2022",

month = jun,

doi = "10.1038/s41571-022-00610-8",

language = "English",

volume = "19",

pages = "385–401",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - COVID-19 vaccines in patients with cancer

T2 - immunogenicity, efficacy and safety

AU - Fendler, Annika

AU - de Vries, Elisabeth G E

AU - GeurtsvanKessel, Corine H

AU - Haanen, John B

AU - Wörmann, Bernhard

AU - Turajlic, Samra

AU - von Lilienfeld-Toal, Marie

PY - 2022/6

Y1 - 2022/6

N2 - Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

AB - Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.

U2 - 10.1038/s41571-022-00610-8

DO - 10.1038/s41571-022-00610-8

M3 - Review article

C2 - 35277694

SN - 1759-4774

VL - 19

SP - 385

EP - 401

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

ER -

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Abstract

Access to Document

Handle.net

Fingerprint

Cite this